1Wang A,Yu BN,Luo CH,et al.Ile 118 Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients[J].Eur J Clin Pharmacol,2005,60(12):843-848.
2Yamada Y,Matsuo H,Watanabe S,et al.Association of a polymorphism of CYP3A4 with type 2 diabetes mellitus[J].Int J Mol Med,2007,20(5):703-707.
3Fukushima-Uesaka H,Saito Y,Watanabe H,et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population[J].Human Mutation,2004,23(1):100.
4Jing Du,Qinghe Xing,Lingyun Xu,et al.Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population[J].Pharmacogenomics,2006,7(6):831-841.
5Hu YF,He J,Chen GL,et al.CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population[J].Clin Chim Acta,2005,353(1-2):187-192.
6Ming-Hsien Tsai,Keh-Ming Lin,Mei-Chun Hsiao,et al.Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response[J].Pharmacogenomics,2010,11(4):537-546.
7Su-Jun Lee,Sang Seop Lee,Hye-Eun Jeong,et al.The CYP3A4*18 allele,the most frequent coding variant in asian populations,does not significantly affect the midazolam disposition in heterozygous individuals[J].Drug Metab Dispos,2007,35(11):2095-2101.
8Jun KR,Lee W,Jang MS,et al.Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea[J].Transplantation,2009,87(8):1225-1231.
10Du J,Yu L,Wang L,et al.Differences in CYP3A41G genotype distribution and haplotypes of CYP3A4,CYP3A5 and CYP3A7 in 3 Chinese populations[J].Clin Chim Acta,2007,383:172-174.
